Table 2.
Association of Val16Ala with 10-year breast cancer survival
| Univariate | Multivariate* | |||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Combined analysis | (n=573) | (n=465) | ||
| Val/Val | 1 (ref.) | 1 (ref.) | ||
| Val/Ala | 1.27 (0.87–1.84) | 0.215 | 1.26 (0.83–1.91) | 0.274 |
| Ala/Ala | 1.96 (1.30–2.94) | 0.001 | 2.19 (1.39–3.34) | 0.001 |
| Val/Ala & Ala/Ala | 1.47 (1.03–2.09) | 0.034 | 1.52 (1.03–2.25) | 0.033 |
| Ptrend | 0.001 | |||
| Val/Val & Val/Ala | 1 (ref.) | 1 (ref.) | ||
| Ala/Ala | 1.67 (1.22–2.27) | 0.001 | 1.91 (1.36–2.67) | <0.001 |
| US Cohort | (n=244) | (n=183) | ||
| Val/Val | 1 (ref.) | 1 (ref.) | ||
| Val/Ala | 1.62 (0.93–2.81) | 0.088 | 1.58 (0.84–2.96) | 0.155 |
| Ala/Ala | 2.24 (1.20–4.18) | 0.011 | 2.44 (1.11–5.37) | 0.027 |
| Val/Ala & Ala/Ala | 1.78 (1.05–3.00) | 0.031 | 1.75 (0.96–3.18) | 0.067 |
| Ptrend | 0.011 | |||
| Val/Val & Val/Ala | 1 (ref.) | 1 (ref.) | ||
| Ala/Ala | 1.63 (1.00–2.66) | 0.050 | 1.71 (0.96–3.06) | 0.066 |
| Norway Cohort | (n=329) | (n=282) | ||
| Val/Val | 1 (ref.) | 1 (ref.) | ||
| Val/Ala | 1.04 (0.62–1.73) | 0.880 | 0.88 (0.49–1.56) | 0.662 |
| Ala/Ala | 1.73 (1.01–2.97) | 0.047 | 1.91 (1.06–3.45) | 0.031 |
| Val/Ala & Ala/Ala | 1.24 (0.77–2.01) | 0.369 | 1.22 (0.73–2.05) | 0.448 |
| Ptrend | 0.033 | |||
| Val/Val & Val/Ala | 1 (ref.) | 1 (ref.) | ||
| Ala/Ala | 1.68 (1.12–2.52) | 0.012 | 1.98 (1.30–3.01) | 0.002 |
*
Cox Proportional-Hazards regression with adjustments for age at diagnosis, cohort, race, tumor size, nodal involvement, tumor grade, estrogen receptor status and p53 mutation.